In a study of 1,077 healthy adults, the experimental vaccine produced two kinds of immune responses that could protect the body against COVID-19.
The vaccine caused no serious side effects, but about 70 percent of people reported fatigue and 68 percent reported a headache, The Wall Street Journal reported.
The results mean that researchers remain on track to have the vaccine ready for mass production by September, according to the Journal.
Phase 3 trials of the vaccine are underway in the U.K., Brazil and South Africa, and a trial involving 30,000 people in the U.S. is set to begin in August.
“There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise,” University of Oxford researcher Sarah Gilbert told the Journal.
Read the full article here.
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
